A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Clinical trial NCT06235801 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06235801
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-22
- Primary completion
- 2027-10-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.